Vioxx Disclosure Emphasizes Need for New Web Resource that Answers Questions About Anti-Epileptic Medi... ( Prescribing for Better Outcomes O...)

Vioxx Disclosure Emphasizes Need for New Web Resource that Answers Questions About Anti-Epileptic Medication Use

Date:4/17/2008

Prescribing for Better Outcomes Offers Unbiased, Comprehensive Analysis of Drug Research; Site Comes in Response to 2004 Pharmaceutical Suit Against Warner-Lambert

CHAPEL HILL, N.C., April 17 /PRNewswire-USNewswire/ --- Physicians and consumers who want fair and balanced information about the most appropriate uses for prescription medications can now find it using a Web-based resource that provides easily accessible, science-based research about drug uses free from pharmaceutical industry influence.

Prescribing for Better Outcomes, a Web-based educational campaign (http://prescribingforbetteroutcomes.org) designed to provide accurate information about the uses of anti-epileptic drugs for the treatment of bipolar disorder, grew out of a global effort to promote evidence-based research and counter the practice of "off-label marketing," in which drug companies promote uses of their medications that may not be supported by science or approved by the U.S. Food and Drug Administration.

"All patients have unique needs. Sometimes, prescribing a drug for an off-label use is the best option," said Dr. John Oldham, M.D., a psychiatrist and Chief of Staff at The Menninger Clinic and the editor of the Journal of Psychiatric Practice. "But when decisions about off-label prescribing are influenced by explicit and deceptive marketing tactics, it lessens our ability as medical professionals to find the best treatment for individual patients."

Prescribing for Better Outcomes (http://prescribingforbetteroutcomes.org) was launched in direct response to a 2004 lawsuit brought by 50 state attorneys general against pharmaceutical manufacturer Pfizer and its subsidiary, Warner-Lambert. The drug company had been charged with using deceptive marketing tactics to promote off-label sales of its anti-epileptic drug, Ne
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. New study may explain Vioxx side-effects
2. Study Points to Cause of Vioxx Heart Risk
3. Vioxx Ban Tied to Rise in Serious GI Trouble
4. The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc.
5. Vioxx Settlement Puts Painkillers Back in the Spotlight
6. Vioxx Settlement Announced
7. Merck Pays More Than $400 Million to Settle Federal, State Medicaid Fraud Investigation Sparked by Qui Tam Whistleblower Case Detailing Marketing Schemes for Vioxx(R), Zocor(R), Several Other Drugs
8. In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market
9. Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits
10. Key Vioxx Research Was Written by Merck, Documents Allege
11. NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information

Post Your Comments:

Vioxx Disclosure Emphasizes Need for New Web Resource that Answers Questions About Anti-Epileptic Medi...( Prescribing for Better Outcomes O...),Health